Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations.
Lim AM, McDowell L, Hurt C, Le Tourneau C, Homma A, Shenouda G, Thomson DJ, Moya-Plana A, Henson C, Szturz P, Day AT, Bates JE, Lazarakis S, Thariat J, Psyrri A, Mehanna H, Yom SS; HNCIG. Lim AM, et al. Among authors: hurt c. Lancet Oncol. 2024 Jul;25(7):e318-e330. doi: 10.1016/S1470-2045(24)00067-6. Lancet Oncol. 2024. PMID: 38936390 Review.
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations.
Lim AM, Le Tourneau C, Hurt C, Laskar SG, Steuer CE, Chow VLY, Szturz P, Henson C, Day AT, Bates JE, Lazarakis S, McDowell L, Mehanna H, Yom SS; HNCIG. Lim AM, et al. Among authors: hurt c. Lancet Oncol. 2024 Jul;25(7):e308-e317. doi: 10.1016/S1470-2045(24)00068-8. Lancet Oncol. 2024. PMID: 38936389 Review.
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD; HVTN 136/HPTN 092 Study Team. Edupuganti S, et al. Among authors: hurt cb. Lancet HIV. 2025 Jan;12(1):e13-e25. doi: 10.1016/S2352-3018(24)00247-9. Epub 2024 Dec 10. Lancet HIV. 2025. PMID: 39667379 Clinical Trial.
Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities.
Estadt AT, Kline D, Miller WC, Feinberg J, Hurt CB, Mixson LS, Friedmann PD, Lowe K, Tsui JI, Young AM, Cooper H, Korthuis PT, Pho MT, Jenkins W, Westergaard RP, Go VF, Brook D, Smith G, Rice DR, Lancaster KE. Estadt AT, et al. Among authors: hurt cb. Harm Reduct J. 2024 Nov 29;21(1):214. doi: 10.1186/s12954-024-01131-6. Harm Reduct J. 2024. PMID: 39614319 Free PMC article.
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083.
Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ; for HPTN 083 Study Team. Clement ME, et al. Clin Infect Dis. 2024 Nov 23:ciae572. doi: 10.1093/cid/ciae572. Online ahead of print. Clin Infect Dis. 2024. PMID: 39579334
Coupling neurologic music therapy with immersive virtual reality to improve executive functions in individuals with Parkinson's disease: A Quasi-Randomized Clinical Trial.
Impellizzeri F, Maggio MG, De Pasquale P, Bonanno M, Bonanno L, De Luca R, Paladina G, Alibrandi A, Milardi D, Thaut M, Hurt C, Quartarone A, Calabrò RS. Impellizzeri F, et al. Among authors: hurt c. Clin Park Relat Disord. 2024 Oct 21;11:100277. doi: 10.1016/j.prdoa.2024.100277. eCollection 2024. Clin Park Relat Disord. 2024. PMID: 39507632 Free PMC article.
Preparation and Rationale for a Patient-Centered Clinical Outcome Assessment Set of Fluid Overload for Drug Development in Nephrotic Syndrome.
Salmon E, Carlozzi NE, Lai JS, Spino C, Wang Y, Capellari E, Scherr R, Sifre K, Sullivan S, Hurt C, Creguer T, Helm K, Lafayette RA, Nachman PH, Selewski DT, Peipert JD. Salmon E, et al. Among authors: hurt c. Glomerular Dis. 2024 Aug 5;4(1):172-182. doi: 10.1159/000539921. eCollection 2024 Jan-Dec. Glomerular Dis. 2024. PMID: 39473996 Free PMC article.
The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors.
Carucci M, Clamp A, Zhou C, Hurt C, Glasspool R, Monaghan PJ, Thirkettle S, Wheatley M, Mahmood M, Narasimham M, Cox T, Morrison H, Campbell S, Nelson A, Holland-Hart D, Hopewell-Kelly N, Thomas A, Porter C, Slusarczyk M, Irving A, Dive C, Adams R, Jayson GC. Carucci M, et al. Among authors: hurt c. BMC Cancer. 2024 Oct 24;24(1):1309. doi: 10.1186/s12885-024-13073-0. BMC Cancer. 2024. PMID: 39448911 Free PMC article.
Transoral Laser or Robotic Surgery Outcomes for Oropharyngeal Carcinoma: Secondary Analysis of the PATHOS Randomized Clinical Trial.
O'Hara JT, Hurt CN, Ingarfield K, Patterson JM, Hutcheson K, Canham JE, Nixon LS, Heiberg CD, Johson S, Evans M, Jones TM. O'Hara JT, et al. Among authors: hurt cn. JAMA Otolaryngol Head Neck Surg. 2024 Oct 10;150(11):1002-11. doi: 10.1001/jamaoto.2024.3371. Online ahead of print. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 39388196 Free PMC article.
339 results